Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 11/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 8/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875891 | 1.00 | NPY1R (0.40) | NPY1RSLC6A4KCNH2ALDH1A1SOAT1 | |
| Hydrochloric Acid SCHEMBL4868453 | 0.99 | NPY1R (0.40) | NPY1RSLC6A4KCNH2ALDH1A1SOAT1 | |
| Hydrochloric Acid SCHEMBL4868441 | 0.99 | NPY1R (0.40) | NPY1RSLC6A4KCNH2ALDH1A1SOAT1 | |
| SCHEMBL4877841 | 0.95 | ALDH1A1 (0.42) | NPY1RSLC6A4KCNH2ALDH1A1SOAT1 | |
| SCHEMBL4877835 | 0.95 | ALDH1A1 (0.42) | NPY1RSLC6A4KCNH2ALDH1A1SOAT1 | |
| SCHEMBL4881335 | 0.88 | NPY1R (0.40) | NPY1RSLC6A4KCNH2ALDH1A1SOAT1 | |
| SCHEMBL4881333 | 0.88 | NPY1R (0.40) | NPY1RSLC6A4KCNH2ALDH1A1SOAT1 | |
| SCHEMBL14194851 | 0.84 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL14194850 | 0.84 | ALDH1A1 (0.43) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4878687 | 0.83 | MEN1 (0.44) | ALDH1A1SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | NPY1R 338/4885SLC6A4 632/4885KCNH2 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.